New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
July 31, 2015
16:22 EDTMRKStocks end week higher in U.S. despite selloff in China
Subscribe for More Information
14:07 EDTMCKLeerink healthcare tech analyst holds analyst/industry conference call
Subscribe for More Information
13:19 EDTMRKNewLink Ebola results promising, says Mizuho
Subscribe for More Information
12:25 EDTCTRPExpedia hits 52-week high after Q2 profit tops estimates
Shares of online travel company Expedia (EXPE) are rising after the company’s second quarter adjusted profit topped analysts’ consensus estimates and it reported strong gross bookings. WHAT'S NEW: After the close on Thursday, Expedia reported Q2 adjusted earnings per share of 89c, topping analysts' consensus estimates of 84c, on revenue of $1.66B, in line with the consensus projection. The company reported adjusted EPS, excluding eLong (LONG), of $1.02. WHAT'S NOTABLE: Expedia reported Q2 room night growth, excluding eLong, grew to 35% year-over-year, with domestic and international room nights growing 24% and 50%, respectively. It reported gross bookings and revenue, excluding eLong, increased 20% and 15%, respectively. Excluding the impact of foreign exchange, gross bookings increased 28%. In Q2, Expedia added nearly 27,000 properties to its global supply portfolio, which now stands at approximately 257,000. ANALYST REACTION: RBC Capital said this morning that Expedia's results were "surprisingly strong," given intra-quarter comments by the company. The firm raised its price target on the name to $140 from $130 and kept an Outperform rating on the shares. PRICE ACTION: In early afternoon trading, Expedia rose $11, or about 10%, to $118.65 on more than twice its average daily trading volume. Earlier in the session, the stock made a fresh 52-week high of $119. Including today’s advance, the shares have gained approximately 50% over the past year. OTHERS TO WATCH: Other online travel companies include Priceline Group (PCLN), which is up 2.3%, Travelzoo (TZOO), which is up 0.6%, Ctrip.com (CTRP), which is up 1.8% and Orbitz Worldwide (OWW) and Tripadvisor (TRIP), whose shares are flat.
11:34 EDTNFLXStocks with call strike movement; FEYE NFLX
Subscribe for More Information
09:02 EDTMCKCintas to acquire ZEE Medical from McKesson for approx. $130M in cash
Subscribe for More Information
08:24 EDTMRKNewLink Genetics announces data suggesting efficacy of Ebola vaccine
NewLink Genetics (NLNK) announced that the international partnership studying the VSV-ZEBOV Ebola vaccine candidate in Guinea has released interim data suggesting that it is effective against Ebola in a large clinical trial. Interim results suggest that the vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection. The VSV-ZEBOV Ebola vaccine candidate was originally developed by the Public Health Agency of Canada, and was subsequently licensed to a subsidiary of NewLink Genetics. In late 2014, Merck (MRK) licensed the vaccine from NewLink Genetics to apply Merck’s vaccine expertise to help accelerate the development of this promising candidate. Merck is now responsible for research, development and manufacturing of the rVSV-ZEBOV vaccine.
08:13 EDTMRKMerck: Investigational ebola vaccine had 100% efficacy in study analysis
Subscribe for More Information
07:31 EDTALKSAlkermes reported solid Q2 financial results, says Leerink
Leerink analyst Michael Schmidt says Alkermes reported solid Q2 financial results driven by stronger than expected Vivitrol sales. All pipeline programs remain on track, Schmidt tells investors in a post-earnings research note. He reiterates an Outperform rating on the stock with a $79 price target.
05:44 EDTNFLXRovi price target lowered to $23 from $27 at JPMorgan
JPMorgan analyst Sterling Auty lowered his price target for Rovi (ROVI) to $23 saying the company's Q2 results and guidance were worse than expected. The Netflix (NFLX) litigation outcome has led to slower sales cycles, Auty tells investors in a research note. He sees an uncertain growth outlook going forward and keeps a Neutral rating on Rovi.
July 30, 2015
19:08 EDTVVUSVIVUS announces restructuring plan, will reduce headcount
Subscribe for More Information
16:22 EDTNFLXRovi to continue pursuing Netflix litigation
Rovi (ROVI) said in its earnings release, "While we are disappointed with the Netflix ruling, we continue to believe in our broader IP licensing business. Our second half focus is on achieving our sales and profit objectives, continuing our big-four renewal negotiations, securing meaningful design wins for our products and continuing to pursue our Netflix litigation."
16:02 EDTVVUSVIVUS reports Q2 EPS (19c), consensus (24c)
Subscribe for More Information
16:00 EDTNFLXOptions Update; July 30, 2015
iPath S&P 500 VIX Short-Term Futures down 11c to 16.05. Option volume leaders: AAPL FB SPLS X TWTR BAC NFLX MU CHK BIDU WFM HPQ LNKD MDLZ XOM
13:06 EDTALKSAlkermes remains well positioned after Q2 results, says JPMorgan
Subscribe for More Information
11:33 EDTCTRPEarnings Watch: Expedia shares up 15.5% since Q1 report
Subscribe for More Information
10:26 EDTNFLXMarriott sees 'solid' RevPAR growth in North America for foreseeable future
Subscribe for More Information
07:12 EDTALKSAlkermes raises FY15 adjusted EPS view to (31c)-(45c) from (37c)-(50c)
Subscribe for More Information
07:10 EDTALKSAlkermes reports Q2 adjusted EPS (9c), consensus (10c)
Subscribe for More Information
July 29, 2015
16:42 EDTMCKMcKesson raises FY16 adjusted EPS view to $12.36-$12.86 from $12.20-$12.70
Subscribe for More Information
16:41 EDTMCKMcKesson raises quarterly dividend 17% to 28c from 24c per share
Subscribe for More Information
16:40 EDTMCKMcKesson sees FY16 adjusted EPS $12.36-$12.86, consensus $12.59
16:39 EDTMCKMcKesson reports Q1 adjusted EPS $3.14, consensus $2.91
Reports Q1 revenue $47.5B, consensus $45.93B.
16:00 EDTNFLXOptions Update; July 29, 2015
Subscribe for More Information
15:08 EDTALKSNotable companies reporting before tomorrow's open
Subscribe for More Information
13:54 EDTALKSEarnings Watch: Alkermes up around 17% since last earnings report
Alkermes (ALKS) is scheduled to report second quarter earnings before the market open on Thursday, July 30 with a conference call scheduled for 8:30 am ET. Alkermes, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. EXPECTATIONS: Analysts are looking for a loss of (10c) per share on revenue of $142.8M, according to First Call. The consensus range for EPS is for a loss of (17c)-(4c) on revenue of $134.5M-$153.28M. LAST QUARTER: Alkermes reported first quarter EPS of 6c, compared to a consensus estimate of a loss of (3c), on revenue of $161.2M against estimates of $146.6M. The company reiterated all of its financial expectations for 2015 that it had previously given on March 9, when it cut its 2015 EPS view to (37c)-(50c) from (27c)-(40c). Q1 revenue from the company's anti-psychotic franchise, including Risperdal were $46.9M, compared to $49.6M for the same period in the prior year. Revenues from Amprya/Famprya were $36.5M, compared to $20.6M for the same period in the prior year. "Our results this quarter reflect strong revenues from our portfolio of key commercial products and focused investment in our promising late-stage pipeline of CNS product candidates that will drive our future growth," commented Alkermes CFO James Frates. Alkermes CEO Richard Pops noted that the company is on the "threshold" of its next growth phase and that Aripiprazole lauroxil, the company's long-acting atypical anti-psychotic for schizophrenia, is moving toward FDA approval and launch later this year. STREET RESEARCH: On June 26, Cowen said the clinical profile for Alkermes' ALKS 3831 continues to look interesting, as the firm's consultants believe data for the drug suggests a profile that would provide a significant benefit over Zyprexa for the treatment of schizophrenia. Cowen reiterated its Outperform rating and $80 price target on Alkermes shares. PRICE ACTION: Alkermes shares are up around 17% since the company's last earnings report on April 30, and are down almost 3% to $67.40 in midday trading ahead of Thursday's earnings release.
09:20 EDTMRKMerck recent weakness creates buying opportunity, says Argus
Subscribe for More Information
July 28, 2015
16:53 EDTMRKOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
16:00 EDTNFLXOptions Update; July 28, 2015
Subscribe for More Information
15:21 EDTMCKNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include MasterCard (MA), consensus 85c... Altria (MO), consensus 71... General Dynamics (GD), consensus $2.06... Anthem (ANTM), consensus $2.75... Praxair (PX), consensus $1.46... Northrop Grumman (NOC), consensus $2.36... McKesson (MCK), consensus $2.91... Eaton (ETN), consensus $1.13... Humana (HUM), consensus $1.63... Hilton (HLT), consensus 23c... International Paper (IP), consensus 92c... Rockwell Automation (ROK), consensus $1.54... Jarden (JAH), consensus 59c... Quintiles (Q), consensus 70c... Tableau Software (DATA), consensus 4c... Garmin (GRMN), consensus 82c... Vantiv (VNTV), consensus 54c... ADT (ADT), consensus 49c.
12:31 EDTMRKOn The Fly: Top stock stories at midday
Stocks on Wall Street began the session in positive territory but turned mixed a short time after the open. The averages gathered themselves again and began an upward drift about an hour into trading, leaving markets near session highs around noon as stocks try to break their string of five consecutive lower closes. ECONOMIC EVENTS: In the U.S., the Case Shiller 20-city home price index rose 1.1% in May to 179.03, missing a forecast for it to rise 1.7% to 180.2. Markit's services PMI for July rose to 55.2, above the expected 55.0 reading. The Richmond Fed factory index rose to 13.0 in July from an upwardly revised 7 in June. Consumer confidence fell to 90.9 in July, down from a revised 99.8 figure for last month and below the expected reading of 100. In China, the Shanghai composite index closed down 1.7%, but only after a volatile session that saw it down as much as 5.1% and up about 1% at different points in the trading day. In Europe, U.K. GDP growth in the second quarter came in at 0.7%, matching the consensus expectation. COMPANY NEWS: Earnings season continued in earnest with UPS (UPS), Ford (F), Pfizer (PFE) and Merck (MRK) each reporting better than expected quarterly profits. UPS, which said its quarterly results gave it confidence in achieving the upper end of its earnings guidance range for the fiscal year, rose more than 5%. Pfizer and Merck each raised their fiscal year earnings guidance ranges, but Pfizer advanced 1.7% following its report while Merck slid nearly 0.5%. Ford, meanwhile, gained 1.8% after backing its fiscal year pre-tax profit view and repeating that it still expects the second half of the year to be stronger than the first half. MAJOR MOVERS: Among the notable gainers was Supervalu (SVU), which jumped 19% after the company reported better than expected first quarter results and also announced that it is exploring a separation of its Save-A-Lot business into a stand-alone, publicly traded company. Also higher was GrubHub (GRUB), which gained over 5% after reporting better than expect top and bottom line results in its second quarter and issuing 2015 guidance that analysts at Stifel said "appears conservative." Among the noteworthy losers was Immunomedics (IMMU), which tumbled 34% after the company's partner, UCB, announced that two Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus did not meet their primary clinical efficacy endpoints in either dose in both studies. Also lower following its earnings reports was Baidu (BIDU), which fell 16.5% and was downgraded by at least four research firms. INDEXES: Near midday, the Dow was up 136.13, or 0.78%, to 17,576.72, the Nasdaq was up 36.37, or 0.72%, to 5,076.14, and the S&P 500 was up 19.42, or 0.94%, to 2,087.06.
10:47 EDTNFLXUBS says YouTube paid service could be $1B business
Google's (GOOG, GOOGL) revenue could increase by about $1B or more if it decides to offer a paid, ad free version of its YouTube website in the U.S., UBS wrote in a note to investors today. The firm made the estimate based on a survey it conducted of U.S. consumers. WHAT'S NEW: YouTube remains well-positioned to benefit from the growth of online video, UBS analyst Eric Sheridan stated. After UBS conducted a survey of U.S. adult consumers, Sheridan reported that the survey found that 27% of U.S. consumers would probably subscribe to a paid, ad free version of YouTube. According to Bloomberg, YouTube has decided to launch such a service in coming months. If only 5% of U.S. YouTube users buy subscriptions to the service, Google's revenue would rise by about $943M, Sheridan estimated. Following the survey, the analyst is more confident that Google will meet his revenue estimates, which exceed consensus levels. Specifically, he predicted that Google's revenue for the second half of 2015 would come in at $32.4B, versus the consensus outlook of $31.8B, while its 2016 revenue would be $72.2B, compared with the consensus estimate of $69.7B. Sheridan kept a $750 price target and Buy rating on the stock. WHAT'S NOTABLE: Other companies that are significantly exposed to online video include Netflix (NFLX), Facebook (FB) and AOL, which has been acquired by Verizon (VZ). PRICE ACTION: In morning trading, Google Class A shares were little changed at $657.55.
09:42 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL BIDU FB NFLX F T FCX TWTR
07:20 EDTMRKBrookings Institute to hold a public meeting
Subscribe for More Information
07:11 EDTMRKMerck reports Q2 Pharmaceutical sales $8.56B
Subscribe for More Information
07:04 EDTMRKMerck narrows FY15 EPS view to $3.45-$3.55, consensus $3.45
Subscribe for More Information
07:03 EDTMRKMerck reports Q2 EPS 86c, consensus 81c
Reports Q2 revenue $9.8B, consensus $9.8B.
06:49 EDTMRKMerck to acquire cCam Biotherapeutics for $95M
Merck and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95M in cash. In addition, cCAM shareholders of record are eligible to receive a total of up to $510M associated with the attainment of certain clinical development, regulatory and commercial milestones. The transaction is subject to certain closing conditions.
06:32 EDTMRKMerck's grazoprevir/elbasvir application accepted by FDA
Subscribe for More Information
July 27, 2015
16:00 EDTNFLXOptions Update; July 27, 2015
Subscribe for More Information
15:03 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
14:43 EDTMRKEarnings Watch: Merck's Keytruda sales will be focus in Q2 results
Subscribe for More Information
10:40 EDTALKSLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
09:36 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL NFLX INTC MU VZ BIDU AMBA
08:32 EDTMRKMerck receives 'positive' CHMP opinion for Zerbaxa
Subscribe for More Information
07:37 EDTMRKAeterna Zentaris starts promoting Saizen for injection in 25 U.S. territories
Subscribe for More Information
06:30 EDTNFLXSky prepares to unveil set-top box, Telegraph reports
Sky is finishing up an advanced set-top box called SkyQ, a device it hopes can help its pay-TV business compete against BT (BT), the Telegraph reports. The new hardware is set to be unveiled in the next few weeks and will offer satellite households an "Apple (AAPL) and Netflix (NFLX) style" experience, the report says, citing industry insiders. Reference Link
July 26, 2015
15:48 EDTNFLXNetflix executive: Expect DVD rentals for 'foreseeable future,' NYT reports
Despite the success of Netflix's streaming service, Hank Breeggemann, general manager of the company's DVD division, told the New York Times to "expect us to continue to ship DVDs for the foreseeable future." The report notes that Netflix is employing cutting-edge technology to streamline the process of shipping DVDs while trimming costs, with Breeggemann adding, "If you cut back on service, you are going to lose your subscriber base." Reference Link
July 24, 2015
15:06 EDTNFLXEarnings Watch: TV networks report as streaming services gain ground
CBS (CBS), Time Warner (TWX), Viacom (VIA, VIAB), and 21st Century Fox (FOX, FOXA) are among TV network companies expected to report quarterly results over the next several weeks, with Comcast (CMCSA, CMCSK) already having reported before the open on July 23. EXPECTATIONS: Time Warner is expected to report EPS of $1.03 on revenue of $6.9B, CBS is expected to report EPS of 73c on revenue of $3.22B, Viacom is expected to report EPS of $1.47 on revenue of $3.22B, and 21st Century Fox is expected to report EPS of 37c on revenue of $6.48B. LAST QUARTER: CBS, Time Warner, and Fox all reported stronger than expected Q1 results, while Viacom reported higher than expected Q2 EPS but missed on revenue. THIS WEEK'S EARNINGS: On the morning of July 23, Comcast reported Q2 EPS of 84c in line with estimates, and revenue of $18.7B versus expectations for $18.14B. Cable customer relationships for the quarter were up 31,000 to 27.3M, driven by increases in double and triple product relationships. During a subsequent conference call, the company noted that TV viewership continues to be under pressure. NEWS: At Re/code's Code Conference on May 27, CBS CEO Leslie Moonves remarked that his network will "probably" sign up for Apple's (AAPL) rumored TV service, and on June 3, CBS announced that its Showtime network will be offered over the internet as a stand-alone streaming service launching in early July for a monthly price of $10.99, with Apple as its first partner. On July 1, Variety quoted sources as saying Viacom was attempting to entice advertisers by offering to construct social-media and digital extensions of traditional TV ad campaigns as the company seeks to move away from Nielsen-based advertising sales. On July 8, the Wall Street Journal reported that Viacom's Paramount Pictures reached an agreement with AMC (AMC) to accelerate the home release of movies, noting that the company hoped to implement the quickened schedule for all new releases beginning later in the year. On July 17, Re/code reported that Viacom held talks to acquire e-commerce and media company Thrillist Media, according to sources. On June 17, 21st Century Fox named James Murdoch as CEO, with founder and former chairman and CEO Rupert Murdoch appointed executive co-chairman alongside Lachlan Murdoch. The Telegraph reported on June 20 that Fox rejected offers for its stake in Sky (SKYAY) from Vodafone (VOD) and Vivendi (VIVHY), potentially signalling an interest in outright purchasing the rest of Sky, according to the report. More recently, the European Commission announced on July 23 that it delivered a statement of objections to Sky and various film studios owned by Comcast, Viacom, Fox, Time Warner, Disney (DIS), and Sony (SNE), discussing anti-trust concerns due to limitations on country-by-country availability of pay-TV services. STREET RESEARCH: On May 12, Pacific Crest said it believes Apple will launch its TV service before the end of the year, saying the move should benefit TV networks as well as Apple itself. On June 24, Brean Capital said Facebook's (FB) agreement with Time Warner to host premier episodes of certain upcoming shows was "a trend worth following," and possibly indicative of Facebook hosting additional TV content in the future. Also on June 24, FBR Capital contended that Netflix (NFLX) was on pace to have a larger 24-hour audience than all traditional broadcast networks, where ratings are seeing declines on average, according to the research firm. Those comments were followed by a July 10 note on Netflix from Morgan Stanley, saying the subscription streaming service was seeing higher time spent per day than any single broadcast network. Moving away from the Netflix factor, on July 10, JPMorgan said CBS shares looked "very attractive" following a recent selloff, though the company saw a downgrade on July 20 from Pivotal, which cited higher costs of capital among other factors. Finally, Citi upgraded Viacom on July 16 to Neutral, citing recent underperformance in the company's shares heading into earnings season.
14:04 EDTNFLXOn The Fly: Weekly technical notes on 'FANG' and divergences
Subscribe for More Information
July 23, 2015
13:53 EDTNFLX“Fab Five” option implied volatility
Subscribe for More Information
11:04 EDTMRKMerck announces EMA acceptance of MAA for grazoprevir/elbasvir
Subscribe for More Information
10:08 EDTMATOptions with decreasing implied volatility
Subscribe for More Information
06:51 EDTNFLXDreamWorks upgraded to Market Perform from Underperform at FBR Capital
FBR Capital analyst Barton Crockett upgraded DreamWorks (DWA) to Market Perform saying growth from licensing more TV shows to Netflix (NFLX) should offset increased competition in core feature films. Crockett raised his price target for shares to $26.
July 22, 2015
15:02 EDTNFLXOptions Update; July 22, 2015
Subscribe for More Information
10:15 EDTNFLX, MATOptions with decreasing implied volatility
Subscribe for More Information
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
July 21, 2015
10:24 EDTNFLX, MATOptions with decreasing implied volatility
Subscribe for More Information
09:35 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL FB IBM TSLA BAC PVA NFLX
July 20, 2015
16:01 EDTNFLXOptions Update; July 20, 2015
Subscribe for More Information
10:13 EDTNFLXOptions with decreasing implied volatility
Subscribe for More Information
09:53 EDTNFLXNetflix falls to session lows, levels to watch
Subscribe for More Information
09:34 EDTNFLXActive equity options trading on open
Subscribe for More Information
July 17, 2015
16:46 EDTCTRPViking Global Investors reports 5.2% passive stake in Ctrip.com
Subscribe for More Information
16:41 EDTNFLXStocks end week higher as Google, Greece bring out the buyers
Stocks ended the week higher and the major averages are back at record highs after Iran agreed to a nuclear deal, Greece's parliament paved the way for the country to receive another bailout by agreeing to new austerity measures and Google (GOOG) gave investors hope that earnings from tech's other heavyweights will be similarly better than expected. MACRO NEWS: In the U.S., retail sales unexpectedly fell 0.3% in June, versus the consensus forecast for growth of 0.3%. The producer prices index showed prices rose 0.4% in June, versus expectations for an increase of 0.2%. The consumer price index rose a seasonally adjusted 0.3% in June from a month earlier, matching the consensus forecast. Compared with last year, consumer prices rose 0.1%, marking the first annual increase since December. Housing starts rose 9.8% to a 1.17M rate in June and building permits rose 7.4% to a 1.34M pace, both of which topped expectations. The NAHB homebuilder sentiment index for July came in at 60, a point better than forecast. The University of Michigan's consumer sentiment reading dropped to 93.3 in the preliminary July figure, which was below the 96.0 reading that was expected. During testimony before Congress, Federal Reserve Chair Janet Yellen stayed on message, stating that the central bank is on track to raise record-low interest rates this year, so long as the labor market and the economy keep improving... In China, exports rose 2.1% from a year earlier during June and imports dropped 6.7%, leaving a trade surplus of $45.8B for the month, the nation's customs administration reported. The nation's GDP was reported to have grown 7% in the second quarter from a year earlier, beating the consensus expectation for growth of 6.8%... In Europe, Greek lawmakers passed the country's austerity agreement and Euro-area finance ministers reportedly agreed in principle to extend a bridge loan to Greece. The loan should help keep Greece afloat while its Prime Minister negotiates the details of the country's latest bailout... Iran reached a deal on restrictions and inspections intended to prevent it from developing nuclear weapons in exchange for the lifting of economic sanctions by six world powers. The agreement still faces a political fight in the U.S. before taking effect, but President Barack Obama has vowed to veto any congressional effort to block its implementation. COMPANY NEWS: Class A shares of Google (GOOG, GOOGL) surged at the end of the week after the search giant reported better than expected revenues and earnings in the second quarter. Research firms all over Wall Street raised their price targets on the stock in the wake of the report... Netflix (NFLX) rallied to a split-adjusted all-time high after the streaming service operator reported stronger than expected second quarter results, including higher than expected Q2 subscriber metrics, prompting a large number of research firms to raise their price targets on the stock... Many of the nation's largest banks reported on their results in the second quarter this week. JPMorgan (JPM), Bank of America (BAC) and Citigroup (C) all posted quarterly profits, excluding certain items, that beat the average estimates of analysts. Wells Fargo (WFC) reported earnings in-line with consensus estimates and revenue somewhat below expectations, while Goldman Sachs (GS) reported headline earnings that appeared to fall far short of the consensus forecast. However, that was due to Goldman's nearly $1.5B in provisions for litigation and regulatory matters. Excluding those provisions, the bank's earnings were ahead of consensus... On the M&A front, Receptos (RCPT) advanced after Celgene (CELG) announced a deal to buy the smaller drugmaker for $232 per share in cash, or a total of about $7.2B net of cash acquired. A number of research firms applauded the deal, especially noting the price Celgene agreed to pay, but cautioned that a rival bidder may still emerge for Receptos. Marathon Petroleum (MPC) gained after MPLX (MPLX), the company's fee-based master limited partnership, agreed to acquire MarkWest Energy (MWE) in a cash and stock deal that implies a total enterprise value for MarkWest of approximately $20B, including the assumption of debt of approximately $4.2B. Micron (MU) rose after The Wall Street Journal reported that China's state-owned Tsinghua Unigroup had offered to acquire the memory chip maker for $23B, or $21 per share... Shares of Twitter (TWTR) spiked Tuesday morning after a questionable takeover report was published on a website that mimicked, but had a different web address, than Bloomberg News. A Bloomberg spokesman said soon afterward that the Twitter takeover story being attributed to the news service was a fake, while a Twitter spokesperson also denied the report of an alleged deal... Macy's (M) jumped after Starboard CEO Jeffrey Smith called the stock his "best idea" for 2015, adding that the shares could be worth $125 each if the company takes steps to maximize the value of its real estate holdings. Amazon (AMZN) announced it sold more units on its first "Prime Day" than the biggest Black Friday ever and had more new members try its Prime service worldwide than any single day in company history. The e-commerce giant noted that its worldwide order growth increased 266% over the same day last year and 18% more than Black Friday 2014, adding that it will "definitely be" doing another Prime Day in the future. A number of semiconductor equipment stocks, including Applied Materials (AMAT) and Lam Research (LRCX), dropped after Intel (INTC) cut its capital expenditures guidance while reporting on its quarterly results. INDEXES: For the week, the Dow gained about 1.05% to close at 18,086.45, the Nasdaq advanced about 3.37% to close at 5,210.14, and the S&P 500 rose about 1.67% to close at 2,126.64.
16:41 EDTNFLXMiramax talks to banks as it explores sale, Bloomberg says
Subscribe for More Information
16:01 EDTNFLXOptions Update; July 17, 2015
Subscribe for More Information
14:35 EDTALKSRecro Pharma entered into supply pact with Alkermes
Subscribe for More Information
12:28 EDTNFLXStocks with call strike movement; ASHR NFLX
Subscribe for More Information
09:35 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL NFLX TSLA GOOG FB GOOGL SLB
07:41 EDTNFLXRovi ruling in Netflix suit may 'embolden' pay TV providers, says Stephens
Subscribe for More Information
06:13 EDTNFLXHulu considering ad-free option, WSJ reports
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use